Abstract 1611P
Background
Living with brain metastasis (BM) causes distress for patients and family carers. Patients report a wide range of physical, social and psychological problems that affect daily life for them and their families. Despite the high prevalence of BM, little is known about the experiences of family carers. This qualitative study explores how family carers of BM patients perceive the information and communication about diagnosis, the health care services provided, and how their lives are affected by the BM.
Methods
This was a prospective qualitative study with individual semi-structured interviews. Participants were interviewed three times; shortly after the BM diagnosis, and then after two and four months. A total of 40 interviews with 18 adult family carers (13 spouses, 2 adult children, 2 siblings) were conducted. Transcripts were analysed using a reflexive thematic analysis. A trajectory matrix was developed for the longitudinal design, searching for overarching themes over time as well as changes in the themes identified.
Results
For many family carers the BM diagnosis was experienced as particularly frightening, given that the metastases were located in the brain. Family carers felt that they lived in a rapidly changing, chaotic and unpredictable situation. They reported working nonstop to coordinate family life, the patient’s health care follow-up, and to maintain a sort of normality in daily life. The situation affected their relationship with the patient, especially daily life activities and communication. The need for information was extensive among most family carers. They emphasized a need for more information about treatment and prognosis to be able to plan for the future. This information need remained high through all interviews.
Conclusions
Being a family carer of a patient with BM implies extensive practical, emotional and psychosocial challenges. The need for continuous information is particularly high, and health care providers should tailor their information to the individual recipient. Palliative care, with a person-centred approach and systematic follow up of the needs of family carers, should be introduced in an early stage.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Oslo University Hospital.
Funding
The Norwegian Cancer Society Pink Ribbon and The Norwegian South-East Health Trust.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1999P - IMreal Cohort 4: Third interim analysis of efficacy and safety in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus carboplatin and etoposide (atezo + CE) as first-line (1L) therapy under real-world conditions (RWCs)
Presenter: Sanjay Popat
Session: Poster session 05
2000P - Efficacy and safety of thoracic radiotherapy after first-line immunotherapy in extensive stage small cell lung cancer: A multi-center retrospective study
Presenter: Jiake Wu
Session: Poster session 05
2001P - Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
Presenter: Vito Longo
Session: Poster session 05
2002P - A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients
Presenter: Marie Porte
Session: Poster session 05
2003P - Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
Presenter: Alessio Bruni
Session: Poster session 05
2004P - PD-L1 Inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence
Presenter: Litang Huang
Session: Poster session 05
2005P - Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
Presenter: Fangfang Gao
Session: Poster session 05
2006P - Immune activation effect and survival of different irradiated sites in ES-SCLC patients treated with radioimmunotherapy: A real-world analysis
Presenter: Min Wu
Session: Poster session 05
2007P - Real-world (rw) outcomes to chemoimmunotherapy and biomarker analysis in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Emmanouil Panagiotou
Session: Poster session 05